Digital Therapeutics for MCI and Alzheimer’s disease: A Regulatory Perspective — Highlights From The Clinical Trials on Alzheimer’s Disease conference (CTAD)

por Shuren, J., Doraiswamy, P. M.
Publicado 2022

The Effect of Vascular Risk Factors on the Efficacy of Rivastigmine Patch and Capsule Treatment in Alzheimer's Disease

por Farlow, M.R., Doraiswamy, P.M., Meng, X., Cooke, K., Somogyi, M.
Publicado 2011

Blueberry Supplementation Effects on Neuronal and Pathological Biomarkers in Subjects at Risk for Alzheimer’s Disease: A Pilot Study

por Doraiswamy, P.M., Miller, M.G., Hellegers, C.A., Nwosu, A., Choe, J., Murdoch, D.M.
Publicado 2023

Alterations in metabolic pathways and networks in Alzheimer's disease

por Kaddurah-Daouk, R, Zhu, H, Sharma, S, Bogdanov, M, Rozen, S G, Matson, W, Oki, N O, Motsinger-Reif, A A, Churchill, E, Lei, Z, Appleby, D, Kling, M A, Trojanowski, J Q, Doraiswamy, P M, Arnold, S E
Publicado 2013

Florbetapir F 18 amyloid PET and 36-month cognitive decline:a prospective multicenter study

por Doraiswamy, P M, Sperling, R A, Johnson, K, Reiman, E M, Wong, T Z, Sabbagh, M N, Sadowsky, C H, Fleisher, A S, Carpenter, A, Joshi, A D, Lu, M, Grundman, M, Mintun, M A, Skovronsky, D M, Pontecorvo, M J
Publicado 2014